Medicine and Dentistry
Mesothelioma
100%
Pleura Mesothelioma
98%
Biological Marker
79%
Malignant Neoplasm
66%
Neoplasm
60%
Non Small Cell Lung Cancer
59%
Lung Cancer
57%
Stomach Cancer
53%
Osteoclast Differentiation Factor
53%
Overall Survival
47%
Atrial Fibrillation
46%
Radiation Therapy
44%
Smoking
39%
Osteoprotegerin
39%
Pemetrexed
38%
Asbestos Exposure
33%
Cohort Analysis
32%
Biopsy
30%
Prognostic Factor
29%
Immunohistochemistry
28%
Alternative Complement Pathway C3 C5 Convertase
28%
Nuclear Factor
28%
Recurrent Disease
27%
Oxaliplatin
26%
Receptor
25%
Retrospective Study
23%
Cancer Incidence
21%
Radiation Pneumonia
21%
Gastrointestinal Stromal Tumor
21%
Systematic Review
21%
Folinic Acid
21%
Fluorouracil
21%
Prospective Study
21%
Drug Megadose
19%
Sinus Rhythm
18%
Diagnosis
17%
Progression Free Survival
16%
Carboplatin
16%
Predictive Factor
15%
In Vitro
15%
Supportive Care
15%
Hazard Ratio
15%
Cancer Risk
14%
Vinorelbine
14%
Mitral Valve Surgery
14%
Leukocyte
14%
Single Nucleotide Polymorphism
13%
Lung Cancer Screening
13%
Visceral Pleura
13%
Squamous Cell Carcinoma
13%
Keyphrases
Malignant Pleural Mesothelioma
32%
Mitral Valve Surgery
21%
Predictive Biomarker
21%
HUNT Study
21%
Clinical Target Volume
21%
Lung Cancer Risk
21%
Ever Smokers
17%
Lung Cancer
14%
Receptor Activator of nuclear factor-κB Ligand (RANKL)
13%
Lung Cancer Screening
12%
Lung Cancer Model
11%
Sensitizing mutations
10%
Epidermal Growth Factor Receptor
10%
Icotinib
10%
Human Gastric Cancer
10%
Cisplatin-induced
10%
Thioredoxin-interacting Protein (TXNIP)
10%
Induced Cell Death
10%
XRCC1
10%
Human Gastric Cancer Cells
10%
Chinese Population
10%
Adrenocortical Carcinoma
10%
Pemetrexed
10%
Vinorelbine
10%
First-line Chemotherapy
10%
Brain Metastases
10%
Lone Atrial Fibrillation
10%
Radiofrequency Catheter Ablation
10%
Receptor Activator of nuclear factor-B Ligand
10%
Phosphorylated Retinoblastoma Protein
10%
Human Lung Cancer Cell Line
10%
Gefitinib
10%
P21 Expression
10%
Malignant Peritoneal Mesothelioma
10%
Cytoplasmic p21
10%
Gastric Cancer Patients
10%
Predictive Role
10%
Synergistic Role
10%
Antiestrogen
10%
Estrogen Effect
10%
Recurrent Ascites
10%
Recombinant Human Endostatin
10%
Undifferentiated Carcinoma
10%
Geometric Margin
10%
Gross Tumor Volume
10%
Re-biopsy
10%
Endostar
10%
Unknown Primary Site
10%
Radiotherapy Plan
10%
Sinus Rhythm
10%
